Regen BioPharma Inc (RGBP)

[scoobey-do]

The following, from Dr. Koos' message, is worth repeating:

Our science is now progressing. While the Company has many exciting pipeline products, we need to focus our limited resources towards what we believe will provide patients and our shareholders the maximum benefit. Thus, we are actively developing a novel CAR T-cell therapy which we call DuraCAR. This cell therapy is designed to utilize our patented shRNA that targets the immune checkpoint NR2F6 in the context of a CAR T-cell. By doing so, we expect that this cell therapy will be able to kill solid tumors as well as leukemias and lymphomas because these cells should be less susceptible to exhaustion and immunosuppression by the tumor microenvironment. We expect additional results from our partner CROs in the coming months. As this program progresses, we will seek out-licensing or asset sale opportunities to progress this product into the clinic.